Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts

British Journal of Pharmacology

Volumn 154, Issue 7, 2008, Pages 1528-1537

  Sugiyama, A ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Chronic atrioventricular block; ECG; QT interval prolongation; Repolarization reserve; Torsades de pointes

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ASTEMIZOLE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANRENOIC ACID; CISAPRIDE; DIURETIC AGENT; DOFETILIDE; GATIFLOXACIN; HALOPERIDOL; HALOTHANE; HISTAMINE H1 RECEPTOR ANTAGONIST; METHOXAMINE; MOXIFLOXACIN; NIFEKALANT; PHOSPHODIESTERASE V INHIBITOR; PROKINETIC AGENT; RISPERIDONE; SEMATILIDE; SILDENAFIL; SOTALOL; SPARFLOXACIN; SULPIRIDE; TERFENADINE; UNINDEXED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARRHYTHMOGENESIS; ATRIOVENTRICULAR BLOCK; DOG; DRUG INDUCED DISEASE; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE REMODELING; HUMAN; MONKEY; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; QT PROLONGATION; RELIABILITY; REVIEW; TORSADE DES POINTES;

ANIMALS; ATRIOVENTRICULAR BLOCK; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MACACA FASCICULARIS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; TORSADES DE POINTES; TOXICITY TESTS; VENTRICULAR REMODELING;

EID: 48149111313     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.240     Document Type: Review

References (91)

1. Akita M, Shibazaki Y, Izumi M, Hiratsuka K, Sakai T, Kurosawa T et al. (2004). Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J Toxicol Sci 29: 63-71.
2. Anderson ME, Mazur A, Yang T, Roden DM (2001). Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 296: 806-810.
3. Ando K, Sugiyama A, Takahara A, Satoh Y, Ishizaka T, Nakamura Y et al. (2007). Analysis of proarrhythmic potential of antipsychotics risperidone and olanzapine in anesthetized dogs. Eur J Pharmacol 558: 151-158.
4. Ando K, Unakami S, Obo M, Sasaki A, Makita Y, Yamamoto Y et al. (2005). QT-prolongation effect of orally administered terfenadine in conscious cynomolgus monkeys - interaction with ketoconazole. Adv Anim Cardiol 38: 9-20.
5. Batey AJ, Coker SJ (2002). Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes. Br J Pharmacol 135: 1003-1012.
6. Belardinelli L, Antzelevitch C, Vos MA (2003). Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 24: 619-625.
7. Brooks RR, Drexler AP, Maynard AE, Al-Khalidi H, Kostreva DR (2000). Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. Proc Soc Exp Biol Med 223: 183-189.
8. Buchanan LV, Kabell G, Brunden MN, Gibson JK (1993). Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 22: 540-549.
9. Carlsson L (2006). In vitro and in vivo models for testing arrhythmogenesis in drugs. J Intern Med 259: 70-80.
10. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G (1993). Proarrhythmic effects of the class III antiarrhythmic agent almokalant - importance of rate of infusion, QT interval dispersion and early afterdepolarizations. Cardiovasc Res 27: 2186-2193.
11. Carlsson L, Almgren O, Duker G (1990). QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 16: 276-285.
12. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G (1997). Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther 282: 220-227.
13. Chen X, Cass JD, Bradley JA, Dahm CM, Sun Z, Kadyszewski E et al. (2005). QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol 146: 792-799.
14. Chiba K, Sugiyama A, Hagiwara T, Takahashi S, Takasuna K, Hashimoto K (2004a). In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome. Eur J Pharmacol 486: 189-200.
15. Chiba K, Sugiyama A, Satoh Y, Shiina H, Hashimoto K (2000). Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades. Toxicol Appl Pharmacol 169: 8-16.
16. Chiba K, Sugiyama A, Takasuna K, Hashimoto K (2004b). Comparison of sensitivity of surrogate markers of drug-induced torsades de pointes in canine hearts. Eur J Pharmacol 502: 117-122.
17. Chiba K, Sugiyama A, Watanabe K, Takasuna K, Hashimoto K (2006). Acute hypokalemia may not be an effective way to sensitize the in situ canine heart for sparfloxacin-induced long QT syndrome. J Pharmacol Sci 100: 88-92.
18. Di Diego JM, Belardinelli L, Antzelevitch C (2003). Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 108: 1027-1033.
19. Di Diego JM, Cordeiro JM, Goodrow RJ, Fish JM, Zygmunt AC, Perez GJ et al. (2002). Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 106: 2004-2011.
20. Eckardt L, Haverkamp W, Mertens H, Johna R, Clague JR, Borggrefe M et al. (1998). Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, D,L-sotalol, and erythromycin. J Cardiovasc Pharmacol 32: 425-434.
21. Farkas A, Leprán I, Papp JG (2002). Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes. J Cardiovasc Pharmacol 39: 287-297.
22. Fish JM, Di Diego JM, Nesterenko V, Antzelevitch C (2004). Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing. Circulation 109: 2136-2142.
23. Hamlin RL (2007). Animal models of ventricular arrhythmias. Pharmacol Ther 113: 276-295.
24. Hondeghem LM, Carlsson L, Duker G (2001). Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103: 2004-2013.
25. Hondeghem LM, Hoffmann P (2003). Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. J Cardiovasc Pharmacol 41: 14-24.
26. Inaba H, Hayami N, Ajiki K, Sugishita Y, Kunishima T, Yamagishi N et al. (2008). Human atrial natriuretic peptide suppresses torsades de pointes in rabbits. Circ J 72: 820-824.
27. Ishizaka T, Takahara A, Iwasaki H, Mitsumori Y, Kise H, Nakamura Y et al. (2008). Comparison of electropharmacological effects of bepridil and sotalol in the halothane-anesthetized dogs. Circ J 72: 1003-1011.
28. Lawrence CL, Bridgland-Taylor MH, Pollard CE, Hammond TG, Valentin J-P (2006). A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of torsades de pointes. Br J Pharmacol 149: 845-860.
29. Lee KW, Kayser SR, Hongo RH, Tseng ZH, Scheinman MM (2004). Famotidine and long QT syndrome. Am J Cardiol 93: 1325-1327.
30. Lu HR, Remeysen P, De Clerck F (2000). Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation. J Cardiovasc Pharmacol 36: 728-736.
31. Lu HR, Vlaminckx E, van de Water A, Rohrbacher J, Hermans A, Gallacher DJ (2006). In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol 553: 229-239.
32. Milberg P, Hilker E, Ramtin S, Cakir Y, Stypmann J, Engelen MA et al. (2007). Proarrhythmia as a class effect of quinolones: increase dispersion of repolarization and triangulation of action potential predict torsades de pointes. J Cardiovasc Electrophysiol 18: 647-654.
33. Ohashi J, Yasuda S, Miyazaki S, Shimizu W, Morii I, Kurita T et al. (2006). Prevention of life-threatening ventricular tachyarrhythmia by a novel and pure class-III agent, nifekalant hydrochloride. J Cardiovasc Pharmacol 48: 274-279.
34. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45.
35. Roden DM (2005). Proarrhythmia as a pharmacogenomic entity: a critical review and formulation of a unifying hypothesis. Cardiovas Res 67: 419-425.
36. Kr blockade: comparison with urethane anesthesia. J Pharmacol Sci 99: 185-190.
37. Satoh Y, Sugiyama A, Chiba K, Tamura K, Hashimoto K (2000a). QT prolonging effects of sparfloxacin, a fluoroquinolone antibiotics, assessed in the in vivo canine model with the monophasic action potential monitoring. J Cardiovasc Pharmacol 36: 510-515.
38. Satoh Y, Sugiyama A, Takahara A, Ando K, Wang K, Honsho S et al. (2005). An antipsychotic and antiemetic drug prochlorperazine delays the ventricular repolarization of the in situ canine heart. J Pharmacol Sci 97: 101-106.
39. Satoh Y, Sugiyama A, Takahara A, Hashimoto K (2004). Electropharmacological and proarrhythmic effects of a class III antiarrhythmic drug nifekalant hydrochloride assessed using the in vivo canine models. J Cardiovasc Pharmacol 43: 715-723.
40. Satoh Y, Sugiyama A, Takahara A, Hashimoto K (2006). A novel monkey proarrhythmia model that can predict the drug-induced torsades de pointes in clinical practice. J Pharmacol Sci 100 (Suppl I): 223P.
41. Satoh Y, Sugiyama A, Tamura K, Hashimoto K (1999). Effects of a class III antiarrhythmic drug, dofetilide, on the in situ canine heart assessed by the simultaneous monitoring of hemodynamic and electrophysiological parameters. Jpn J Pharmacol 81: 79-85.
42. Satoh Y, Sugiyama A, Tamura K, Hashimoto K (2000b). Effects of magnesium sulfate on the haloperidol-induced QT Prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential. Jpn Circ J 64: 445-451.
43. Satoh Y, Sugiyama A, Tamura K, Hashimoto K (2000c). Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: potential utility of mexiletine for the treatment of drug-induced long QT syndrome. Jpn J Pharmacol 83: 327-334.
44. Shiina H, Sugiyama A, Takahara A, Satoh Y, Hashimoto K (2000). Comparison of the electropharmacological effects of verapamil and propranolol in the halothane-anesthetized in vivo canine model under monophasic action potential monitoring. Jpn Circ J 64: 777-782.
45. Shimizu W, McMahon B, Antzelevitch C (1999). Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de pointes in models of acquired and congenital long QT syndrome. J Cardiovasc Electrophysiol 10: 154-164.
46. Sicouri S, Moro S, Litovsky S, Elizari MV, Antzelevitch C (1997). Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol 8: 1269-1279.
47. Steidl-Nichols JV, Hanton G, Leaney J, Liu RC, Leishman D, McHarg A et al. (2008). Impact of study design on proarrhythmia prediction in the SCREENIT rabbit isolated heart model. J Pharmacol Toxicol Methods 57: 9-22.
48. Sugiyama A, Aye NN, Katahira S, Hagihara A, Hashimoto K (1997a). Effects of magnesium sulfate on the canine cardiovascular system complicating astemizole overdose. J Cardiovasc Pharmacol 29: 795-800.
49. Sugiyama A, Aye NN, Katahira S, Saitoh M, Hagihara A, Matsubara Y et al. (1997b). Effects of nonsedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring. Toxicol Appl Pharmacol 143: 89-95.
50. Sugiyama A, Hashimoto K (1998). Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring. Toxicol Appl Pharmacol 152: 261-269.
51. Sugiyama A, Hashimoto K (1999). Can the MAP technique be applied to detect delayed afterdepolarization? Electrophysiologic and pharmacologic evidence. J Cardiovasc Pharmacol 34: 46-52.
52. Kr channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes. Jpn Pharmacol 88: 414-421.
53. Sugiyama A, Ishida Y, Satoh Y, Aoki S, Hori M, Akie Y et al. (2002a). Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT prolonging drugs. Jpn J Pharmacol 88: 341-350.
54. Sugiyama A, Ni C, Arita J, Eto K, Xue YX, Hashimoto K (1996). Effects of antihypoxic and neuroprotective drug, lubeluzole, on repolarization phase of canine heart assessed by monophasic action potential recording. Toxicol Appl Pharmacol 139: 109-114.
55. Sugiyama A, Satoh Y, Hashimoto K (2001a). Acute electropharmacological effects of intravenously administered amiodarone assessed in the in vivo canine model. Jpn J Pharmacol 87: 74-82.
56. Sugiyama A, Satoh Y, Hashimoto K (2001b). Electrophysiologic effects of a new phosphodiesterase III inhibitor, toborinone (OPC-18790), assessed in an in vivo canine model. J Cardiovasc Pharmacol 38: 268-277.
57. Sugiyama A, Satoh Y, Hashimoto K (2001c). In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicol Appl Pharmacol 173: 120-128.
58. Sugiyama A, Satoh Y, Ishida Y, Yoneyama M, Yoshida H, Hashimoto K (2002b). Pharmacological and electrophysiological characterization of junctional rhythm during radiofrequency catheter ablation of the atrioventricular node: possible involvement of neurotransmitters from autonomic nervous system. Circ J 66: 696-701.
59. Sugiyama A, Satoh Y, Shiina H, Takahara A, Yoneyama M, Hashimoto K (2001d). Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. J Cardiovasc Pharmacol 38: 940-946.
60. Sugiyama A, Satoh Y, Shiina H, Takeda S, Hashimoto K (2002c). Torsadegenic action of the antipsychotic drug sulpiride assessed using in vivo canine models. J Cardiovasc Pharmacol 40: 235-245.
61. Sugiyama A, Satoh Y, Takahara A, Ando K, Wang K, Honsho S et al. (2004a). Electropharmacological effects of a spironolactone derivative, potassium canrenoate assessed in the halothaneanesthetized canine model. J Pharmacol Sci 96: 436-443.
62. Sugiyama A, Satoh Y, Takahara A, Nakamura Y, Shimizu-Sasamata M, Sato S et al. (2003). Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems. Eur J Pharmacol 466: 137-146.
63. Sugiyama A, Satoh Y, Wada K, Nomura H, Nakamura Y, Hashimoto K (2004b). Torsadogenic action of QT-prolonging drugs, astemizole and haloperidol, assessed by the canine chronic atrioventricular block model. J Pharmacol Sci 94 (Suppl I): 151P.
64. Sugiyama A, Takahara A, Hashimoto K (1999). Electrophysiological, cardiohemodynamic and β-blocking actions of a new ultra-short acting β-blocker ONO-1101 assessed by the in vivo canine model in comparison with esmolol. J Cardiovasc Pharmacol 34: 70-77.
65. Sugiyama A, Takahara A, Satoh Y, Nakamura Y, Sakamoto K, Wakasa Y (2007). Biochemical, anatomical and electrophysiological adaptations in a monkey torsades de points proarrhythmia model. J Pharmacol Toxicol Methods 56: e36.
66. Takahara A, Nakamura Y, Sugiyama A (2007a). New predictive marker for proarrhythmic potential of drugs assessed in the canine chronic atrioventricular block model. J Pharmacol Sci 103 (Suppl I): 109P.
67. Takahara A, Sakamoto K, Sugiyama A (2006a). New proarrhythmia model of monkey can qualitatively and quantitatively predict clinical risks of QT-interval prolonging drugs. J Mol Cell Cardiol 41: 1073.
68. Takahara A, Sugiyama A, Dohmoto H, Yoshimoto R, Hashimoto K (2000). Electrophysiological and cardiohemodynamic effects of AH-1058, a new type calcium channel blocker, assessed by the in vivo canine model. Jpn J Pharmacol 83: 107-112.
69. Takahara A, Sugiyama A, Hashimoto K (2005a). Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation. Br J Pharmacol 146: 561-567.
70. + channel blocker-induced QT interval prolongation. Biol Pharm Bull 29: 827-829.
71. 1 blocker terfenadine-induced torsades de pointes arrhythmias. Br J Pharmacol 147: 634-641.
72. Takahara A, Sugiyama A, Satoh Y, Hashimoto K (2003a). Effects of mexiletine on the canine model of sparfloxacin-induced long QT syndrome. Eur J Pharmacol 476: 115-122.
73. 1 receptor antagonist terfenadine assessed in the in vivo canine heart model: comparison of the rate-correcting methods for the ventricular repolarization periods. Yamanashi Med J 19: 89-99.
74. Takahara A, Sugiyama A, Satoh Y, Iwasaki H, Nakamura Y, Hashimoto K (2007b). The chronic atrioventricular block dog as a model of lethal ventricular tachyarrhythmia: cardiovascular and neurohumoral profiles and its potential arrhythmogenic mechanisms. Basic Clin Pharmacol Toxicol 101: 35-40.
75. 2+ channel blocker cilnidipine assessed in the chronic atrioventricular conduction block dogs. J Pharmacol Sci 96: 219-223.
76. Kr blockade. Eur J Pharmacol 507: 169-177.
77. Takahara A, Sugiyama A, Satoh Y, Yoneyama M, Hashimoto K (2003b). Cardiovascular effects of Y-27632, a selective Rho-associated kinase inhibitor, assessed in the halothane-anesthetized canine model. Eur J Pharmacol 460: 51-57.
78. Thomsen MB, Beekman JDM, Attevelt NJM, Takahara A, Sugiyama A, Chiba K et al. (2006a). No proarrhythmic properties of the antibiotics moxifloxacin or azithromycin in anesthetized dogs with chronic-AV block. Br J Pharmacol 149: 1039-1048.
79. Thomsen MB, Matz J, Volder PGA, Vos MA (2006b). Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther 112: 150-170.
80. Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, Van Opstal JM et al. (2004). Increased short-term variability of repolarization predicts D-sotalol-induced torsades de pointes in dogs. Circulation 110: 2453-2459.
81. Usui T, Sugiyama A, Ishida Y, Satoh Y, Sasaki Y, Hashimoto K (1998). Simultaneous assessment of the hemodynamic, cardiomechanical and electrophysiological effects of terfenadine on the in vivo canine model. Heart Vessels 13: 49-57.
82. Van Opstal JM, Schoenmakers M, Verduyn SC, de Groot SH, Leunissen JD, Der Hulst FF et al. (2001). Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 104: 2722-2727.
83. Volders PGA, Sipido KR, Vos MA, Kulcsár A, Verduyn SC, Wellens HJJ (1998). Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes. Circulation 98: 1136-1147.
84. Vos MA, de Groot SHM, Verduyn SC, van der Zande J, Leunissen HDM, Cleutjens JPM et al. (1998). Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation 98: 1125-1135.
85. Woosley RL (2008). Pharmacologic agents associated with acquired prolonged QT interval and/or induced torsades de pointes. The University of Arizona CERT http://www.torsades.org [accessed 30 April 2008].
86. Yan GX, Antzelevitch C (1998). Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 98: 1928-1936.
87. Yan GX, Wu Y, Liu T, Wang J, Marinchak RA, Kowey PR (2001). Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 103: 2851-2856.
88. Yoneyama M, Sugiyama A, Yoshida H, Satoh Y, Hashimoto K (2002). Cardiovascular effects of L-158,809, a new angiotensin type 1 receptor antagonist, assessed using the halothane-anesthetized in vivo canine model. Jpn J Pharmacol 89: 192-196.
89. Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Kugiyama K, Hashimoto K (2002a). Effects of disopyramide and mexiletine on the terminal repolarization process of the in situ heart, assessed using the halothane-anesthetized, in vivo canine model. Circ J 66: 857-862.
90. Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Yoneyama M, Kugiyama K et al. (2002b). Comparison of in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug sematilide using the canine chronic AV block model. Circ J 66: 758-762.
91. Zabel M, Hohnloser SH, Behrens S, Woosley RL, Franz MR (1997). Differential effects of D-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart. J Cardiovasc Electrophysiol 8: 1239-1245.